Literature DB >> 30004237

Proteomic analysis of aortic smooth muscle cell secretions reveals an association of myosin heavy chain 11 with abdominal aortic aneurysm.

Utako Yokoyama1, Noriaki Arakawa2,3, Ryo Ishiwata1, Shota Yasuda4, Tomoyuki Minami5, Motohiko Goda4, Keiji Uchida5, Shinichi Suzuki4, Masataka Matsumoto6, Nobusato Koizumi6, Masataka Taguri7, Hisashi Hirano8, Koichi Yoshimura9,10, Hitoshi Ogino6, Munetaka Masuda5,6, Yoshihiro Ishikawa1.   

Abstract

Abdominal aortic aneurysm (AAA) is a life-threatening disease, and no disease-specific circulating biomarkers for AAA screening are currently available. We have identified a smooth muscle cell (SMC)-specific biomarker for AAA. We cultured aneurysmal tunica media that were collected from eight patients undergoing elective open-repair surgeries. Secreted proteins in culture medium were subjected to liquid chromatography/tandem mass spectrometry. Myosin heavy chain 11 (myosin-11) was identified as a SMC-specific protein in the tunica media-derived secretions of all patients. We then examined myosin-11 protein concentrations by ELISA in plasma samples from patients with AAA ( n = 35) and age-matched healthy control subjects ( n = 34). Circulating myosin-11 levels were significantly higher in patients with AAA than control subjects. The area under the receiver-operating characteristic curve (AUC) of myosin-11 was 0.77, with a specificity of 65% at a sensitivity of 91%. Multivariate logistic regression analysis showed a significant association between the myosin-11 level and presence of AAA. When the myosin-11 level was combined with hypertension, it improved the prediction of AAA (AUC 0.88) more than hypertension per se. We then investigated the correlation between aortic diameter and circulating myosin-11 levels using AAA serum samples from patients undergoing endovascular aneurysm repair ( n = 20). Circulating myosin-11 levels were significantly correlated with maximum aortic diameter. Furthermore, changes in myosin-11 concentrations from the baseline 12 mo after endovascular aneurysm repair were associated with those in aortic diameter. These data suggest that circulating levels of myosin-11, which is a SMC-specific myosin isoform, may be useful as a biomarker for AAA. NEW & NOTEWORTHY Extensive studies have revealed that inflammation- or proteolysis-related proteins are proposed as biomarkers for abdominal aortic aneurysm (AAA). Changes in these protein concentrations are not specific for smooth muscle, which is a major part of AAA pathologies. Hence, no disease-specific circulating markers for AAA are currently available. We found, using secretome-based proteomic analysis on human AAA tunica media, that myosin heavy chain 11 was associated with AAA. Circulating myosin heavy chain 11 may be a new tissue-specific AAA marker.

Entities:  

Keywords:  abdominal aortic aneurysm; biomarkers; myosin heavy chain; smooth muscle

Mesh:

Substances:

Year:  2018        PMID: 30004237     DOI: 10.1152/ajpheart.00329.2018

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  4 in total

1.  Serum Lipid Oxidative Stress Products as Risk Factors Are the Candidate Predictive Biomarkers for Human Abdominal Aortic Aneurysms.

Authors:  Feng Shi; Changcheng Ma; Chao Ji; Mu Li; Xun Liu; Yanshuo Han
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

2.  Identification of crucial genes involved in pathogenesis of regional weakening of the aortic wall.

Authors:  Hong Lin Zu; Hong Wei Liu; Hai Yang Wang
Journal:  Hereditas       Date:  2021-12-02       Impact factor: 3.271

3.  Discovery of novel biomarkers for atherosclerotic aortic aneurysm through proteomics-based assessment of disease progression.

Authors:  Hiroaki Yagi; Mitsuhiro Nishigori; Yusuke Murakami; Tsukasa Osaki; Sayaka Muto; Yutaka Iba; Kenji Minatoya; Yoshihiko Ikeda; Hatsue Ishibashi-Ueda; Takayuki Morisaki; Hitoshi Ogino; Hiroshi Tanaka; Hiroaki Sasaki; Hitoshi Matsuda; Naoto Minamino
Journal:  Sci Rep       Date:  2020-04-14       Impact factor: 4.379

4.  Lenvatinib halts aortic aneurysm growth by restoring smooth muscle cell contractility.

Authors:  Albert Busch; Jessica Pauli; Greg Winski; Sonja Bleichert; Ekaterina Chernogubova; Susanne Metschl; Hanna Winter; Matthias Trenner; Armin Wiegering; Christoph Otto; Johannes Fischer; Judith Reiser; Julia Werner; Joy Roy; Christine Brostjan; Christoph Knappich; Hans-Henning Eckstein; Valentina Paloschi; Lars Maegdefessel
Journal:  JCI Insight       Date:  2021-08-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.